title: Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients.
abstract: Available immunomodulatory and conventional steroid treatment regimens provide a limited symptomatic benefit for patients with progressive multiple sclerosis (MS). We performed an open trial on the short-term efficacy of repeated intrathecal application of the sustained release steroid triamcinolone acetonide (TCA) in 27 progressive MS patients. Six TCA administrations, performed every third day, reduced the Expanded Disability Status Scale (EDSS) score [initial: 5.4+/-1.3, 3-7.5 (mean+/-SD, range); end: 4.9+/-1.1; 2.5-6.5; P<0.001] and significantly increased the walking distance and speed in particular after the fourth TCA injection. Concomitantly serially determined cerebrospinal fluid (CSF) markers of cell injury, neuron-specific enolase, total tau-protein, S-100, and beta-amyloid did not significantly change within the interval of TCA treatment. No serious side effects appeared. We conclude that repeat intrathecal injection of 40 mg TCA provides a substantial benefit in progressive MS patients with predominant spinal symptoms and does not alter CSF markers of neuronal cell injury.
authors.affiliation: Department of Neurology, Kamillus-Klinik, Asbach, and Department of Neurology, St Josef-Hospital, Ruhr-University, Bochum, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Hoffmann
authors.forename: W
authors.initials: W
authors.lastname: Kuhn
authors.forename: S
authors.initials: S
authors.lastname: Schimrigk
authors.forename: S
authors.initials: S
authors.lastname: Islamova
authors.forename: K
authors.initials: K
authors.lastname: Hellwig
authors.forename: C
authors.initials: C
authors.lastname: Lukas
authors.forename: N
authors.initials: N
authors.lastname: Brune
authors.forename: D
authors.initials: D
authors.lastname: Pöhlau
authors.forename: H
authors.initials: H
authors.lastname: Przuntek
authors.forename: T
authors.initials: T
authors.lastname: Müller
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004185:Disability Evaluation; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007278:Injections, Spinal / Q000379:methods; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000503:physiopathology; D010751:Phosphopyruvate Hydratase / Q000134:cerebrospinal fluid; D009418:S100 Proteins / Q000134:cerebrospinal fluid; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D016138:Walking
chemical_list: D000893:Anti-Inflammatory Agents; D009418:S100 Proteins; D010751:Phosphopyruvate Hydratase; D014222:Triamcinolone Acetonide